Blueshift Asset Management’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-10,840
Closed -$94.6K 606
2025
Q1
$94.6K Buy
+10,840
New +$137K 0.04% 367
2021
Q3
Sell
-12,108
Closed -$2.37M 1307
2021
Q2
$2.37M Buy
12,108
+10,013
+478% +$1.81M 0.13% 187
2021
Q1
$379K Buy
+2,095
New +$362K 0.04% 571

Other funds holding TXG

Blueshift Asset Management's TXG Position: Q2 2025 in Review

Blueshift Asset Management sold out of 10x Genomics (TXG) in Q2 2025, closing a stake of 10,840 shares — an estimated $94.6K sold.

Blueshift Asset Management first reported a position in TXG in Q1 2021 and held it in 3 quarters. The position peaked at $2.37M in Q2 2021. 297 funds tracked by Wall St. Rank hold TXG as of Q2 2025.

  • Blueshift Asset Management reported no remaining 10x Genomics position as of Q2 2025 after selling out during the quarter.
  • Blueshift Asset Management sold 10,840 10x Genomics shares in Q2 2025, an estimated $94.6K.
  • Blueshift Asset Management first reported a position in 10x Genomics in Q1 2021 and held it in 3 quarters.
  • Blueshift Asset Management's 10x Genomics position peaked at $2.37M in Q2 2021.
  • 297 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2025.

Based on Blueshift Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.